The impact of sex on treatment and outcome in relation to histological subtype in patients with resectable gastric cancer: Results from the randomized CRITICS trial

Abstract Background and Objective This study aims to investigate the impact of sex on outcome measures stratified by histological subtype in patients with resectable gastric cancer (GC). Methods A post‐hoc analysis of the CRITICS‐trial, in which patients with resectable GC were treated with perioperative therapy, was performed. Histopathological characteristics and survival were evaluated for males and females stratified for histological subtype (intestinal/diffuse). Additionally, therapy‐related toxicity and compliance were compared. Results Data from 781 patients (523 males) were available for analyses. Female sex was associated with a distal tumor localization in intestinal ( p = 0.014) and diffuse tumors ( p < 0.001), and younger age in diffuse GC ( p = 0.035). In diffuse GC, tumor‐positive resection margins were also more common in females than males (21% vs. 10%; p = 0.020), specifically at the duodenal margin. During preoperative chemotherapy, severe toxicity occurred in 327 (63%) males and 184 (71%) females ( p = 0.015). Notwithstanding this, relative dose intensities were not significantly different between sexes. Conclusions Positive distal margin rates were higher in females with diffuse GC, predominantly at the duodenal site. Females also experience more toxicity, but this neither impacts dose intensities nor surgical resection rates. Clinicians should be aware of these different surgical outcomes when treating males and females with GC.